The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: AIM giant ASOS to move to London Main Market

Thu, 13th Jan 2022 08:24

(Alliance News) - Online fashion retailer ASOS said Thursday it plans to move to the London Main Market from AIM.

ASOS has dominated the junior market for the past 20 years as its largest, or one of its largest, stocks, with a market capitalisation of GBP2.45 billion.

"ASOS directors believe that given ASOS's size and scale, now is the appropriate time to move from AIM to a premium Main Market listing," the company said, explaining it thinks the move will raise its corporate profile and recognition, and increase investment in its shares by global institutions.

The company said it will move its listing by the end of February. JP Morgan will act as sponsor for the Main Market admission, which won't involve any fund raise.

In conjunction with the shift, ASOS has hired Patrick Kennedy as senior independent director. Kennedy, the former chief executive of Irish betting firm Paddy Power - now Flutter Entertainment - is the chair of Bank of Ireland Group.

ASOS also provided a trading update for the last four months of 2021.

Total revenue rose by 2% to GBP1.39 billion from GBP1.36 billion a year before. In constant currency, the increase was 5%. UK sales rose by 13%, while EU sales rose by 2% and US sales by 11%, both at constant currency. However, Rest of World sales fell by 15% at constant currency and by 20% at actual rates.

Gross margin narrowed by 400 basis points to 43.0%, as expected, ASOS said, due to clearance activity. The product returns rate has normalised in line with expectations.

ASOS said it full-year guidance remains unchanged at 10% to 15% revenue growth and adjusted pretax profit of GBP110 million to GBP140 million.

"Our listing on AIM for the past 20 years has been an important part of ASOS's development, but the time is now right to move to the Main Market as we focus on delivering our medium-term guidance and longer-term growth ambitions," said Chief Operating Officer Mat Dunn.

ASOS shares were up 8.5% at 2,450.00 pence.

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: down 0.2% at 7,536.86

----------

Hang Seng: up 0.1% at 24,429.77

Nikkei 225: closed down 1.0% at 28,489.13

S&P/ASX 200: closed up 0.5% at 7,474.40

----------

DJIA: closed up 38.30 points, 0.1%, at 36,290.32

S&P 500: closed up 0.3% at 4,726.35

Nasdaq Composite: closed up 0.2% at 15,188.39

----------

EUR: up at USD1.1463 (USD1.1425)

GBP: up at USD1.3730 ((USD1.3693)

USD: down at JPY114.50 (JPY114.73)

Gold: up at USD1,826.88 per ounce (USD1,822.60)

Oil (Brent): down at USD84.24 a barrel (USD84.68)

(changes since previous London equities close)

----------

ECONOMICS AND GENERAL

----------

Thursday's key economic events still to come

0930 GMT UK BoE quarterly bank liabilities survey

1030 EST US EIA weekly natural gas storage report

0830 EST US producer price index

0830 EST US initial jobless claims

----------

A second consecutive day of almost unilaterally negative coverage by the press of UK Prime Minister Boris Johnson features widespread calls for his resignation after his apology during Prime Minister's Questions. Johnson admitted at the beginning of PMQs he attended a lockdown party in the No 10 garden on 20 May, 2020. He offered an apology but said he thought it classified as a work event and therefore would fall within the rules. In response to repeated calls to resign from members of opposition parties, including Labour Leader Keir Starmer, Johnson asked an official inquiry be allowed to "establish the facts". Much of Thursday's media coverage focused on growing discontent within the PM's own party. The Guardian says his future is on a 'knife's-edge', with some Conservative MPs openly calling for his resignation while others speak off-the-record.

----------

BROKER RATING CHANGES

----------

Jefferies raises Mears Group to 'Buy' (Hold) - price target 275 (210) pence

----------

BofA cuts IAG to 'Neutral' (Buy) - price target 180 (240) pence

----------

Morgan Stanley resumes Smiths Group with 'Equal-Weight' - target 1,580 pence

----------

COMPANIES - FTSE 100

----------

Tesco, the UK's largest supermarket chain, said it delivered a strong third quarter and Christmas trading performance, bolstered by the grocer's "unwavering" commitment to value for customers. For the 19 weeks to January 8, like-for-like retail sales were up 2.6% compared to the same period the year before. Over the Christmas period alone, like-for-like sales grew 3.2% year-on-year. Tesco said as a result of stronger-than-expected sales to date, it now expects retail operating profit for financial 2022 slightly above the top-end of its previous GBP2.5 billion to GBP2.6 billion guidance range. It posted retail operating profit of GBP1.99 billion in financial 2021. "Despite growing cost pressures and supply chain challenges in the industry, we continued to invest to protect availability, doubled down on our commitment to deliver great value and offered our strongest ever festive range. This put us in a strong position to meet customers' needs as, once again, Covid-19 led to a greater focus on celebrating at home. As a result, we outperformed the market, growing market share and strengthening our value position," said Chief Executive Officer Ken Murphy.

----------

Housebuilder Persimmon hailed its "excellent" performance throughout 2021 and said the long-term fundamentals of the UK housing market remain strong. Persimmon said it delivered 14,551 new home completions in 2021, up from 13,575 in 2020, with an average selling price of GBP237,050, up from GBP230,534. The York-based housebuilder said total revenue in 2021 was GBP3.61 billion, up from GBP3.33 billion in 2020. New housing revenue was GBP3.45 billion, up from GBP3.13 billion. Addressing sector concerns, Persimmon said it agreed with the UK government that leaseholders should not have to pay to remove flammable cladding. Persimmon said it constructed only a "very small proportion" of buildings affected by this issue, which caused the deadly fire at the Grenfell Tower in 2017. In common with the rest of the housebuilding industry, it will shortly begin paying the cladding levy announced in the UK budget, it noted.

----------

In addition, Persimmon appointed Jason Windsor as its new chief financial officer, hired from insurer Aviva to succeed Mike Killoran, who will be retiring in mid-January. Aviva noted the announcement and said a search for a new CFO is underway.

----------

Pharmaceutical firm AstraZeneca has signed a collaboration agreement with Scorpion Therapeutics. Astra will pay Scorpion USD75 million upfront in cash and will have an exclusive over up to three drugs developed using the Scorpion drug discovery platform. The partnership will develop oncology treatments, focusing on hard-to-target cancer proteins. "The new collaboration focuses on a class of proteins called transcription factors, which control gene expression and can regulate important cellular processes including cell growth and survival," Astra explained. "Many transcription factors have long been identified as important targets for new cancer treatments and as drivers of disease, but have previously been considered 'undruggable' using conventional drug discovery approaches."

----------

COMPANIES - FTSE 250

----------

Food, clothing and homewares retailer Marks & Spencer said it put in a strong performance in its financial third quarter and over the Christmas period. For the 13 weeks to January 1, group sales were GBP3.27 billion, up 19% from the same time a year before. As a result of performance over the period, M&S said it was more confident of its ability to deliver the increased guidance it set, and now expects full-year profit before tax and adjusting items of at least GBP500 million. "Trading over the Christmas period has been strong, demonstrating the continued improvements we've made to product and value. Clothing & Home has delivered growth for the second successive quarter, supported by robust online and full price sales growth. Food has maintained its momentum, outperforming the market over both 12 and 24 months," said CEO Steve Rowe.

----------

COMPANIES - GLOBAL

----------

Crown Resorts said it has received a revised takeover proposal from US private equity firm Blackstone. The Australian gambling operator said the offer was AUD13.10 per Crown Resorts share in cash. This is a AUD0.60 increase compared to Blackstone's previous offer of AUD12.50 per share in cash received back in November and is the third offer by Blackstone. Blackstone's original offer was for AUD11.85 per share in cash. Crown shares closed up 8.8% to AUD12.65 in Sydney on Thursday. Blackstone already has a 10% stake in Crown Resorts, having bought the shares from Melco Resorts & Entertainment Ltd for AUD8.15 per share in April 2020.

----------

Thursday's shareholder meetings

Blue Prism Group PLC - GM re takeover by SS&C Technologies

Centrica PLC - GM re sale of Spirit Energy

JPMorgan Japanese Investment Trust PLC - AGM

Kefi Gold & Copper PLC - GM re share placing

Victoria PLC - GM re issue of preferred shares

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
27 Mar 2024 08:02

LONDON BRIEFING: Diploma makes buy; Astra wins Japan drug approvals

(Alliance News) - Stocks in London opened in a muted fashion on Wednesday, with some unease lingering in equity markets ahead of a US inflation reading later in the week.

Read more
26 Mar 2024 10:18

China to speed up 'new productive forces', vice president says

BEIJING, March 26 (Reuters) - China will accelerate the development of "new productive forces" and bolster stability and security for the global economy, Vice President Han Zheng told an investment forum in Beijing, as the world's no.2 economy seeks to reassure anxious foreign firms.

Read more
25 Mar 2024 12:09

LONDON MARKET MIDDAY: Stocks make tepid start to new week

(Alliance News) - Stock prices in London were down at midday on Monday, giving back some gains from last week, when equities were boosted by central bank decisions and accompanying statements which investors saw as dovish.

Read more
25 Mar 2024 09:04

LONDON MARKET OPEN: FTSE 100 treads water, FTSE 250 declines

(Alliance News) - The FTSE 100 in London traded flat early Monday, while the pound remained below the USD1.26 mark, as Bank of England Governor Andrew Bailey suggested rate cuts may happen soon.

Read more
25 Mar 2024 08:40

TOP NEWS: AstraZeneca wins US approval for rare nervous system disease

(Alliance News) - AstraZeneca PLC on Monday said its Ultomiris treatment has been approved by the US Food & Drug Administration as the first and only long-acting C5 complement inhibitor to treat neuromyelitis optica spectrum disorder in adults.

Read more
25 Mar 2024 07:59

LONDON BRIEFING: AstraZeneca wins US approval, Kingfisher profit down

(Alliance News) - London's FTSE 100 is set to open lower on Monday, giving back some of last week's progress, when equities were boosted by hope of interest rate cuts.

Read more
25 Mar 2024 07:23

AstraZeneca gets FDA approval for Ultomiris treatment

(Sharecast News) - AstraZeneca has announced that its autoimmune disease treatment Ultomiris has been given the green light by US regulators.

Read more
21 Mar 2024 16:43

AstraZeneca's Tagrisso successful in treating lung cancer

(Alliance News) - AstraZeneca PLC on Thursday reported positive findings following a phase III trial of its lung cancer Tagrisso treatment.

Read more
19 Mar 2024 08:56

TOP NEWS: AstraZeneca to buy Fusion in deal worth over USD2 billion

(Alliance News) - AstraZeneca PLC on Tuesday said it will buy Fusion Pharmaceuticals Inc, a Canada-based clinical-stage biopharmaceutical company developing "next-generation" radioconjugates.

Read more
19 Mar 2024 07:05

AstraZeneca to buy US-listed Fusion Phrama for $2bn

(Sharecast News) - AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn.

Read more
18 Mar 2024 16:09

UK dividends calendar - next 7 days

Tuesday 19 March 
Jarvis Securities PLCdividend payment date
Wednesday 20 March 
Virgin Money UK PLCdividend payment date
Thursday 21 March 
abrdn Asia Focus PLCdividend payment date
abrdn Private Equity Opportunities Trust PLCex-dividend payment date
AIB Group PLCex-dividend payment date
Beazley PLCex-dividend payment date
BlackRock World Mining Trust PLCex-dividend payment date
British American Tobacco PLCex-dividend payment date
Chemring Group PLCex-dividend payment date
CLS Holdings PLCex-dividend payment date
Conduit Holdings Ltdex-dividend payment date
Craneware PLCex-dividend payment date
Crest Nicholson Holdings PLCex-dividend payment date
Diverse Income Trust PLCex-dividend payment date
Fonix Mobile PLCex-dividend payment date
FW Thorpe PLCex-dividend payment date
Glanbia PLCex-dividend payment date
GlobalData PLCex-dividend payment date
Globalworth Real Estate Investments Ltdex-dividend payment date
Goodwin PLCex-dividend payment date
Gore Street Energy Storage Fund PLCex-dividend payment date
Hargreaves Services PLCex-dividend payment date
HgCapital Trust PLCex-dividend payment date
Hikma Pharmaceuticals PLCex-dividend payment date
Jardine Matheson Holdings LDex-dividend payment date
London Finance & Investment Group PLCex-dividend payment date
Maven Income & Growth VCT 3 PLCex-dividend payment date
Maven Income & Growth VCT 5 PLCex-dividend payment date
MTI Wireless Edge Ltdex-dividend payment date
Nichols PLCex-dividend payment date
NWF Group PLCex-dividend payment date
Palace Capital PLCex-dividend payment date
Pearson PLCex-dividend payment date
Pembroke VCT B PLCex-dividend payment date
Primorus Investments PLCex-dividend payment date
Schroders PLCex-dividend payment date
Triple Point Energy Transition PLCex-dividend payment date
Tristel PLCex-dividend payment date
VPC Specialty Lending Investments PLCdividend payment date
Friday 22 March 
easyJet PLCdividend payment date
FRP Advisory Group PLCdividend payment date
Gulf Investment Fund PLCdividend payment date
Henderson Opportunities Trust PLCdividend payment date
Hercules Site Services PLCdividend payment date
Impax Asset Management Group PLCdividend payment date
JLEN Environmental Assets Group Ltddividend payment date
JPMorgan Multi-Asset Growth & Income PLCdividend payment date
Mattioli Woods PLCdividend payment date
Mobeus Income & Growth 2 VCT PLCdividend payment date
Mobeus Income & Growth 4 VCT PLCdividend payment date
Ramsdens Holdings PLCdividend payment date
Riverstone Credit Opportunities Income PLCdividend payment date
Ruffer Investment Co Ltddividend payment date
Samuel Heath & Sons PLCdividend payment date
Troy Income & Growth Trust PLCdividend payment date
Unilever PLCdividend payment date
Monday 25 March 
AstraZeneca PLCdividend payment date
Endeavour Mining PLCdividend payment date
Mountview Estates PLCdividend payment date
Shell PLCdividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 14-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
18 Mar 2024 14:08

AstraZenca hails Imfinzi and Lynparza results on endometrial cancer

(Alliance News) - AstraZeneca PLC on Monday reported positive findings following the analysis of results from a phase III probe of its Imfinzi and Lynparza cancer treatments.

Read more
14 Mar 2024 10:01

TOP NEWS: AstraZeneca buys France's Amolyt Pharma for USD1 billion

(Alliance News) - AstraZeneca PLC on Thursday said it has struck a deal to acquire Amolyt Pharma SAS, strengthening its late-stage rare disease pipeline.

Read more
14 Mar 2024 07:52

LONDON BRIEFING: Astra makes USD1.05 billion buy; Halma backs outlook

(Alliance News) - London's FTSE 100 is set to tread water after the opening bell sounds on Thursday, as investors look to a batch of US data to come in the early afternoon.

Read more
14 Mar 2024 07:16

AstraZeneca snaps up rare disease specialist Amolyt for $1.05bn

(Sharecast News) - Biopharma giant AstraZeneca has announced the acquisition of French biotech firm Amolyt Pharma for up to $1.05bn to beef up its late-stage rare disease pipeline.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.